

Biphasic insulin aspart 30 (NovoMix 30) – 30% soluble insulin and 70% protamine crystalised insulin (No. 06/02)
Novo Nordisk Limited

Summary of Recommendation

5 July 2002

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Not recommended for use within the NHS in Scotland.

REASONS FOR ADVICE

This drug reduces blood sugar to a greater extent after breakfast and evening meal, but to a lesser extent after lunch, than existing treatment. It has no clear advantage in terms of global glycaemic control as demonstrated by HbA1c. There is no reduction in hypoglycaemic episodes to justify the overall increase in cost.

Professor David H Lawson
Chairman